ArticleBlood cancer journal2024

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.

Yan-Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.